<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645046</url>
  </required_header>
  <id_info>
    <org_study_id>2008MMXX2CoA005</org_study_id>
    <nct_id>NCT01645046</nct_id>
  </id_info>
  <brief_title>The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia</brief_title>
  <official_title>The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia: a Randomized, Double-blinded, Placebo-controlled, Multi-center Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the lipid lowering effects and clinical safety of a&#xD;
      natural hypolipidemic compound, coenzyme A （CoA） capsule in Chinese patients with moderate&#xD;
      dyslipidemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperlipidemia plays important roles in the development and progression of atherosclerosis.&#xD;
      Modulating lipid levels has been shown to reduce the development of atherosclerosis and&#xD;
      incidence of cardiovascular disease. The HMG-CoA reductase inhibitors (also known as statins)&#xD;
      are the most effective agents available in the management of hyperlipidemia and prevention of&#xD;
      major cardiovascular events. Although statin based therapy is commonplace in primary and&#xD;
      secondary prevention, several economical, clinical and safety issues have been raised, so&#xD;
      that there is ongoing research into new, safer and more effective agents to be used alone or&#xD;
      in combination with existing cardiovascular drugs.&#xD;
&#xD;
      Coenzyme A (CoA) is a ubiquitous essential cofactor that plays a central role in the&#xD;
      metabolism of carboxylic acids, including short- and long-chain fatty acids, as well as&#xD;
      carbohydrate and protein. In the metabolic pathway of lipid, CoA participates in fatty acid&#xD;
      β-oxidation, promoting triglyceride (TG) catabolism. Previous research revealed that&#xD;
      insufficiency of CoA in vivo influenced fatty acid β-oxidation catabolism and impaired&#xD;
      clearance of TG from plasma, which was supposed to be one plausible reason resulting in type&#xD;
      Ⅱb and Ⅳ hyperlipoproteinemia. In addition, epidemiological studies showed the prevalence of&#xD;
      serum lipids level increased with age, which may be related to the reduction of CoA synthesis&#xD;
      in aging individuals. Moreover, studies on animals have given evidence to prove that&#xD;
      supplement of CoA had normalizing activity on plasma lipids in dyslipidemia.&#xD;
&#xD;
      Pantethine is a versatile and very well tolerated hypolipidemic agent that can decrease serum&#xD;
      triglycerides, LDL cholesterol, and apolipoprotein B, while increasing HDL cholesterol and&#xD;
      apolipoprotein A-I. Pantethine is the disulfide of pantetheine which per se occurs naturally&#xD;
      as a product of coenzyme A catabolism. Theoretically, antihyperlipidemia effect of CoA should&#xD;
      be more directly and effectively than pantethine. Researches on rabbits and rats models prove&#xD;
      that high dose CoA orally can relieve fasting hyperlipidemia and insulin resistance induced&#xD;
      by high fat diet. So far there has not been sufficient clinical research data to support the&#xD;
      efficacy of CoA in dyslipidemia patients. The present study shows, for the first time, the&#xD;
      safety, effectiveness of oral CoA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of TG levels.</measure>
    <time_frame>4 and 8 weeks after administration.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of TC, LDL-C, and HDL-C levels.</measure>
    <time_frame>4 and 8 weeks after administration.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">294</enrollment>
  <condition>Hyperlipoproteinemia</condition>
  <arm_group>
    <arm_group_label>Coenzyme A 200mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coenzyme A 200mg per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule without coenzyme A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coenzyme A 400mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coenzyme A 400mg per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme A</intervention_name>
    <description>Coenzyme A 200mg per day.</description>
    <arm_group_label>Coenzyme A 200mg</arm_group_label>
    <other_name>Low dose coenzyme A therapy.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme A</intervention_name>
    <description>Coenzyme A 400mg per day.</description>
    <arm_group_label>Coenzyme A 400mg</arm_group_label>
    <other_name>High dose coenzyme A therapy.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule without coenzyme A.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Controls.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  TG 2.3～6.5mmol/l meeting the China National Cholesterol Education Programme diagnostic&#xD;
             criteria of hyperlipidemia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. TC &gt;7.5 mmol/l or LDL-C &gt;3.6 mmol/l&#xD;
&#xD;
          2. Body Mass Index &gt; 30 kg/m2&#xD;
&#xD;
          3. drug induced secondary hypercholesterolemia (such as dibenzothiazine, contraceptive&#xD;
             agent or adrenal cortex hormone)&#xD;
&#xD;
          4. pregnancy&#xD;
&#xD;
          5. acute coronary syndrome, acute myocardial infarction or undergone a revascularization&#xD;
             procedure within 6 months&#xD;
&#xD;
          6. acute liver disease or hepatic dysfunction, as determined by levels of alanine&#xD;
             aminotransferase (ALT) or aspartate aminotransferase levels (AST) more than 3-fold the&#xD;
             upper normal limit&#xD;
&#xD;
          7. nephrotic syndrome or serum creatinine (Cr) (≥179 µmol/L) and creatine phosphokinase&#xD;
             (CK) more than 3-fold the upper normal limit&#xD;
&#xD;
          8. primary hypothyroidism&#xD;
&#xD;
          9. psychiatric patients and HIV-infected patients&#xD;
&#xD;
         10. poorly controlled hypertension, as indicated by a Systolic Blood Pressure &gt;180 mmHg or&#xD;
             Diastolic Blood Pressure &gt;110 mmHg&#xD;
&#xD;
         11. Type I diabetes mellitus（DM）, poorly controlled Type II DM (BS&gt;11.0 mmol/L ) or Type&#xD;
             II DM with LDL-C &gt;2.6 mmol/L.Patients using immunosuppressive drugs, prohibited&#xD;
             medication or other lipid-lowing drugs were also excluded. Subjects were also&#xD;
             ineligible for the study if they had any severe disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junzhu Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang University</affiliation>
  </overall_official>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>July 17, 2012</study_first_submitted>
  <study_first_submitted_qc>July 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2012</study_first_posted>
  <last_update_submitted>July 18, 2012</last_update_submitted>
  <last_update_submitted_qc>July 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang University</investigator_affiliation>
    <investigator_full_name>Jiangtao Lai</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 21, 2013</submitted>
    <returned>March 29, 2013</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

